Indivior Acquires Opiant Pharmaceuticals
November 14, 2022
Indivior PLC will acquire Opiant Pharmaceuticals, Inc. for $20.00 per share in cash (approximately $145 million aggregate) plus up to $8.00 per share in contingent value rights tied to OPNT003 revenue milestones. The acquisition strengthens Indivior's addiction-treatment portfolio by adding Opiant's OPNT003 intranasal opioid overdose candidate and earlier-stage pipeline assets, and is expected to be accretive after the second full year of OPNT003 launch.
- Buyers
- Indivior PLC
- Targets
- Opiant Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.